Nowarta Biopharma is focused on the clinical development of botanical treatments aimed at combating Human Papillomavirus (HPV). The company has introduced Nowarta110, the world's first botanical topical drug specifically designed to treat plantar warts caused by HPV. Their clinical research has demonstrated promising results, including a Phase I/II randomized double-blind study that reported a complete lesion clearance rate of 64.3% with no serious adverse events. This highlights the potential of botanical therapies in addressing viral conditions, particularly those associated with HPV.

In addition to its work on plantar warts, Nowarta is expanding its research pipeline to include treatments for cervical infections and COVID-19, with plans for Phase I and II fast-track clinical trials in 2024. The company has also conducted extensive in-vitro and in-vivo studies to assess the efficacy of Nowarta110 against various cancers, including cervical, melanoma, and breast cancer, demonstrating zero toxicity in previous studies. With a strong emphasis on safety and efficacy, Nowarta Biopharma is positioning itself as a leader in botanical drug development for viral and oncological conditions.

United States

Nowarta Biopharma, Inc.is a pharmaceutical company headquartered in Huntington Beach, California. Founded in 2001 by Dr. Kiani, Nowarta has been engaged in the clinical development of botanical treatments in the global fight against diseases.

Nowarta Biopharma

Company Details